1. Home
  2. PII vs LQDA Comparison

PII vs LQDA Comparison

Compare PII & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Polaris Inc.

PII

Polaris Inc.

HOLD

Current Price

$54.03

Market Cap

3.4B

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$34.00

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PII
LQDA
Founded
1954
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.1B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
PII
LQDA
Price
$54.03
$34.00
Analyst Decision
Hold
Strong Buy
Analyst Count
12
10
Target Price
$57.50
$38.60
AVG Volume (30 Days)
713.9K
1.7M
Earning Date
04-27-2026
06-15-2026
Dividend Yield
4.85%
N/A
EPS Growth
N/A
51.81
EPS
N/A
N/A
Revenue
$7,152,000,000.00
$158,320,000.00
Revenue This Year
$1.52
$993.31
Revenue Next Year
$4.29
$219.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1031.18
52 Week Low
$30.92
$11.26
52 Week High
$75.25
$46.67

Technical Indicators

Market Signals
Indicator
PII
LQDA
Relative Strength Index (RSI) 27.11 45.29
Support Level $46.03 $30.48
Resistance Level $60.88 $36.07
Average True Range (ATR) 2.52 2.66
MACD -1.08 -0.19
Stochastic Oscillator 3.41 42.07

Price Performance

Historical Comparison
PII
LQDA

About PII Polaris Inc.

Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to pontoon and deck boat users. It is slated to divest its Indian motorcycle brand to Carolwood in the first quarter of 2026. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: